Critical issues in dengue vaccine development

Current Opinion in Infectious Diseases

Volumn 24, Issue 5, 2011, Pages 442-450

  Thomas, Stephen J ^a   Endy, Timothy P ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

dengue virus; development; vaccine

Indexed keywords

DENGUE VACCINE;

AEDES AEGYPTI; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; ENVIRONMENTAL IMPACT; GENETIC PREDISPOSITION; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOGENICITY; MEMBRANE FUSION; NONHUMAN; PHENOTYPE; PUBLIC HEALTH PROBLEM; REVIEW; SENSITIVITY AND SPECIFICITY; SEROTYPE; VIRUS CELL INTERACTION; VIRUS TRANSMISSION; WILD TYPE;

ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; HUMANS; WORLD HEALTH;

EID: 80052496440     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834a1b0b     Document Type: Review

References (62)

1. Kyle JL, Harris E. Global spread and persistence of dengue. Annu Rev Microbiol 2008; 62:71-92.
2. Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr Infect Dis Rep 2010; 12:157-164.
3. Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the impact of international travel. Med Clin North Am 2008; 92:1377-1390.
4. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004; 10 (12 Suppl):S98-S109. (Pubitemid 40018233)
5. Holmes EC, Twiddy SS. The origin, emergence and evolutionary genetics of dengue virus. Infect Genet Evol 2003; 3:19-28. (Pubitemid 36437583)
6. Twiddy SS, Holmes EC, Rambaut A. Inferring the rate and time-scale of dengue virus evolution. Mol Biol Evol 2003; 20:122-129. (Pubitemid 36077906)
7. Halstead SB. The XXth century dengue pandemic: need for surveillance and research. World Health Stat Q 1992; 45:292-298.
8. Halstead SB, Yamarat C, Scanlon JE. The Thai hemorrhagic fever epidemic of 1962 (a preliminary report). J Med Assoc Thai 1963; 46:449-462.
9. Zhang W, Chipman PR, Corver J, et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol 2003; 10:907-912. (Pubitemid 37386099)
10. Chavez JH, Silva JR, Amarilla AA, Moraes Figueiredo LT. Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization. Biologicals 2010; 38:613-618.
11. Matsui K, Gromowski GD, Li L, Barrett AD. Characterization of a dengue typespecific epitope on dengue 3 virus envelope protein domain III. J Gen Virol 2010; 91:2249-2253.
12. Modis Y, Ogata S, Clements D, Harrison SC. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 2005; 79:1223-1231. (Pubitemid 40053904)
13. Lok SM, Kostyuchenko V, Nybakken GE, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 2008; 15:312-317. (Pubitemid 351654038)
14. Pierson TC, Xu Q, Nelson S, et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 2007; 1:135-145. (Pubitemid 46554914)
15. Rodriguez-Madoz JR, Belicha-Villanueva A, Bernal-Rubio D, et al. Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J Virol 2010; 84:9760-9774.
16. Rodriguez-Madoz JR, Bernal-Rubio D, Kaminski D, et al. Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J Virol 2010; 84:4845-4850.
17. Ashour J, Laurent-Rolle M, Shi PY, Garcia-Sastre A. NS5 of dengue virus mediates STAT2 binding and degradation. J Virol 2009; 83:5408-5418.
18. Ubol S, Phuklia W, Kalayanarooj S, Modhiran N. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis 2010; 201:923-935.
19. Balas C, Kennel A, Deauvieau F, et al. Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains. J Infect Dis 2011; 203: 103-108.
20. Coller BA, Clements DE, Martyak T, et al. Advances in flavivirus vaccine development. IDrugs 2010; 13:880-884.
21. Murrell S, Wu SC, Butler M. Review of dengue virus and the development of a vaccine. Biotechnol Adv 2011; 29:239-247.
22. Trent D, Shin J, Hombach J, et al. WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11-12 May 2009. Vaccine 2010; 28:8246-8255.
23. Pugachev KV, Guirakhoo F, Trent DW, Monath TP. Traditional and novel approaches to flavivirus vaccines. Int J Parasitol 2003; 33:567-582. (Pubitemid 36638538)
24. Miller N. Recent progress in dengue vaccine research and development. Curr Opin Mol Ther 2010; 12:31-38.
25. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis 2009; 9:678-687.
26. Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010; 338:129-143.
27. Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest 2004; 113:946-951. (Pubitemid 38544112)
28. Imrie A, Roche C, Zhao Z, et al. Homology of complete genome sequences for dengue virus type-1, from dengue-fever-and dengue-haemorrhagic- feverassociated epidemics in Hawaii and French Polynesia. Ann Trop Med Parasitol 2010; 104:225-235.
29. Rico-Hesse R. Dengue virus evolution and virulence models. Clin Infect Dis 2007; 44:1462-1466. (Pubitemid 46801591)
30. Rothman AL. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol 2010; 338:83-98.
31. Rothman AL, Green S, Vaughn DW, et al. Dengue hemorrhagic fever. In: Saluzzo JF, Dodet B, editors. Factors in the emergence of arbovirus diseases. Paris, France: Elsevier; 1997. pp. 109-116.
32. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50.
33. Endy TP, Anderson KB, Nisalak A, et al. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl Trop Dis 2011; 5:e975.
34. Halstead SB. Epidemiological studies of Thai haemorrhagic fever. Bull World Health Organ 1966; 35:80-81.
35. Halstead SB. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 1970; 42:350-362.
36. Halstead SB, Mahalingam S, Marovich MA, et al. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 2010; 10:712-722.
37. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 1970; 42:311-328.
38. Rothman AL. Viral pathogenesis of dengue infections. In: Gubler DJ, Kuno G, editors. Dengue and dengue hemorrhagic fever. New York: CAB International; 1997. pp. 245-272.
39. Lin CC, Huang YH, Shu PY, et al. Characteristic of dengue disease in Taiwan. Am J Trop Med Hyg 2010; 82:731-739.
40. Balmaseda A, Hammond SN, Perez L, et al. Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg 2006; 74:449-456. (Pubitemid 46774369)
41. Halstead SB, Lan NT, Myint TT, et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis 2002; 8:1474-1479. (Pubitemid 36008787)
42. Kliks SC, Nimmannitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988; 38:411-419. (Pubitemid 18086128)
43. Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004; 189:990-1000. (Pubitemid 38373090)
44. Halstead SB. In vivo enhancement of dengue virus infection in Rhesus monkeys by passively transferred antibody. J Infect Dis 1979; 140:527-533. (Pubitemid 10172725)
45. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 1989; 11 (Suppl 4): S830-S839.
46. Sun W, Nisalak A, Gettayacamin M, et al. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J Infect Dis 2006; 193:1658-1665. (Pubitemid 43839470)
47. Pierson TC, Diamond MS. Molecular mechanisms of antibodymediated neutralisation of flavivirus infection. Expert Rev Mol Med 2008; 10:e12.
48. Innis BL, Eckels KH. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 2003; 69 (6 Suppl):1-4.
49. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9. (Pubitemid 30049026)
50. Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002; 185:1213-1221. (Pubitemid 34439127)
51. Watanaveeradej V, Simasathien S, Nisalak A, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg (in press).
52. Durbin AP, Schmidt A, Elwood D, et al. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. J Infect Dis 2011; 203:327-334.
53. Bennett SN, Holmes EC, Chirivella M, et al. Selection-driven evolution of emergent dengue virus. Mol Biol Evol 2003; 20:1650-1658. (Pubitemid 41070827)
54. Worobey M, Rambaut A, Holmes EC. Widespread intra-serotype recombination in natural populations of dengue virus. Proc Natl Acad Sci USA 1999; 96:7352-7357. (Pubitemid 29299665)
55. Tolou HJ, Couissinier-Paris P, Durand JP, et al. Evidence for recombination in natural populations of dengue virus type 1 based on the analysis of complete genome sequences. J Gen Virol 2001; 82:1283-1290. (Pubitemid 32519758)
56. Myat Thu H, Lowry K, Jiang L, et al. Lineage extinction and replacement in dengue type 1 virus populations are due to stochastic events rather than to natural selection. Virology 2005; 336:163-172. (Pubitemid 40693951)
57. Adams B, Holmes EC, Zhang C, et al. Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci USA 2006; 103:14234-14239. (Pubitemid 44453009)
58. Adams B, Boots M. Modelling the relationship between antibody-dependent enhancement and immunological distance with application to dengue. J Theor Biol 2006; 242:337-346. (Pubitemid 44232814)
59. Zhang C, Mammen MP Jr, Chinnawirotpisan P, et al. Clade replacements in dengue virus serotypes 1 and 3 are associated with changing serotype prevalence. J Virol 2005; 79:15123-15130. (Pubitemid 43032295)
60. Aaskov J, Buzacott K, Thu HM, et al. Long-term transmission of defective RNA viruses in humans and Aedes mosquitoes. Science 2006; 311:236-238. (Pubitemid 43108190)
61. Lin SR, Hsieh SC, Yueh YY, et al. Study of sequence variation of dengue type virus in naturally infected mosquitoes and human hosts: implications for transmission and evolution. J Virol 2004; 78:12717-12721.
62. Craig S, Thu HM, Lowry K, et al. Diverse dengue type 2 virus populations contain recombinant and both parental viruses in a single mosquito host. J Virol 2003; 77:4463-4467. (Pubitemid 36350988)